[1] Ferlay J, Soerjomataram I, Dikshit R, et al.Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5): E359-386.
[2] Siegel R L, Miller K D, Jemal A.Cancer statistics[J].CA Cancer J Clin, 2015, 65(1): 5-29.
[3] Tritschler S , Erdelkamp R , Stief C , et al. Neuroendokrines Prostatakarzinom[J].Der Urol, 2017, 56(11): 1475-1484.
[4] Zaffuto E, Pompe R, Zanaty M, et al.Contemporary incidence and cancer control outcomes of primary neuroendocrine prostate cancer: A seer database Analysis[J].Clin Genitourin Cacer, 2017, 15 (5): e793-e800.
[5] Humphrey P A, Moch H, Cubilla A L, et al.The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours[J].Eur Urol, 2016, 70 (1): 106-119.
[6] Epstein J I, Amin M B, Beltran H, et al.Proposed morphologic classification of prostate cancer with neuroendocrine differentiation[J].Am J Surg Pathol, 2014, 38 (6): 756-767.
[7] Bhandari R, Vengaloor Thomas T, Giri S, et al.Small Cell Carcinoma of the Prostate: A Case Report and Review of the Literature[J].Cureus, 2020, 12 (2): e7074.
[8] Basch E, Loblaw D A, Oliver T K, et al.Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline[J].J Clin Oncol, 2014, 32(30): 3436-3448.
[9] Carroll P H, Mohler J L.NCCN Guidelines Updates: Prostate Cancer and Prostate Cancer Early Detection[J]. J Natl Compr Canc Netw, 2018, 16 (5S): 620-623.
[10] Humphrey P A.Histological variants of prostatic carcinoma and their significance[J]. Histopathology, 2012, 60 (1): 59-74.
[11] Weichselbaum R R, Hellman S.Oligometastases revisited[J].Nat Rev Clin Oncol, 2011, 8 (6): 378-382.
[12] Weichselbaum R R, Hellman S.Oligometastases[J]. J Clin Oncol, 1995, 13 (1): 8-10.
[13] Ward J F, Slezak J M, Blute M L, et al.Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15- year outcome[J]. BJU Int, 2005, 95 (6): 751-756.
[14] Comen E, Norton L, Massagué J.Clinical implications of cancer self-seeding[J]. Nat Rev Clin Oncol, 2011, 8 (6): 369-377.
[15] Leyh-Bannurah S R, Gazdovich S, Budäus L, et al. Local Therapy Improves Survival in Meta-static Prostate Cancer[J]. Eur Urol, 2017, 72 (1): 118-124.
[16] Nouri M, Ratther E, Stylianou N, et al.Androgentargeted therapy-induced epithelial mesenchymal plasticity and neuroendocrine transdifferentiation in prostate cancer: An opportunity for intervention[J].Front Oncol, 2014. DOI: 10.3389/fonc.2014.00370
[17] Matei D V, Renne G, Pimentel M, et al.Neuroendocrine differentiation in castration-resistant prostate cancer: A systematic diagnostic attempt[J].Clin Genitourin Cancer, 2012, 10(3): 164-173.
[18] Beltran H, Tagawa S T, Park K, et al.Challenges in recognizing treatment-related neuroendocrine prostate cancer[J].J Clin Oncol, 2012, 30(36): e386-389.
[19] Grigore A D, Ben-Jacob E, Farach-Carson M C.Prostate cancer and neuroendocrine differentiation: more neuronal, less endocrine? [J].Front Oncol, 2015. DOI: 10.3389/fonc. 2015.00037
[20] Nicolas M, Maria D S, Erik B.Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is another Standard. European Urology [J]. 2018, 73 (3): 316-321.
[21] LU X, Horner J W, Paul E, et al.Effective Combinatorial Immunotherapy for Castration Resistant Prostate Cancer[J]. Nature, 2017, 543 (7647): 728-732.
